Company intelligence / Profile preview

MÁV

Ownership: Private
Development stage: Other

Overview

Launched in June 2025 by FAST under AS²Bio accelerator, MavriX Bio aims to deliver the first AAV-based investigational gene replacement therapy for Angelman syndrome into clinical trials. The program builds on research from Dr. Jim Wilson’s laboratory at University of Pennsylvania/Gemma Bio and represents a major step toward disease-modifying treatment where none currently exist.

Therapeutic areas: Neurology
Modalities: Gene therapy (AAV-delivered gene replacement)Gene editing
Industry: Biotech

Partnerships

University of Pennsylvania/Gemma Bio research collaboration; managed under FAST/AS²Bio umbrella.

Beyond the preview

Go deeper on MÁV.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MÁV.

Explore the full profile